Denali Therapeutics (DNLI) Announces Proposed $250M Offering of Common Stock

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC are acting as joint book-running managers for the offering. Berenberg Capital Markets LLC, Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC are acting as co-managers for the offering.

You May Also Be Interested In

• Oklo launches new $1B at-the-market stock offering program
• Nautilus Biotechnology (NAUT) files $300M mixed shelf
• Jefferies on SolarEdge (SEDG): 'The Turnaround Looks to be Over'